Courting Hope In Alzheimer’s: Intellect Neurosciences Sues Pfizer For $2 Million Licensing Fee
This article was originally published in The Pink Sheet Daily
Executive Summary
Company claims a milestone payment was triggered when it received a U.S. patent on its Antisenilin monoclonal antibody platform technology for Alzheimer’s disease.